MX2020004220A - Anticuerpos anti-glico-muc1 y sus usos. - Google Patents
Anticuerpos anti-glico-muc1 y sus usos.Info
- Publication number
- MX2020004220A MX2020004220A MX2020004220A MX2020004220A MX2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A MX 2020004220 A MX2020004220 A MX 2020004220A
- Authority
- MX
- Mexico
- Prior art keywords
- glyco
- antibodies
- muc1
- antigen
- present disclosure
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2017/058036 WO2019083506A1 (en) | 2017-10-24 | 2017-10-24 | ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004220A true MX2020004220A (es) | 2020-10-05 |
Family
ID=66247577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004220A MX2020004220A (es) | 2017-10-24 | 2017-10-24 | Anticuerpos anti-glico-muc1 y sus usos. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3700936A4 (enExample) |
| JP (2) | JP7358367B2 (enExample) |
| KR (2) | KR102608763B1 (enExample) |
| CN (1) | CN111479828B (enExample) |
| AU (1) | AU2017436815B2 (enExample) |
| BR (1) | BR112020008001A2 (enExample) |
| CA (1) | CA3078812A1 (enExample) |
| IL (1) | IL274202A (enExample) |
| MX (1) | MX2020004220A (enExample) |
| WO (1) | WO2019083506A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078812A1 (en) * | 2017-10-24 | 2019-05-02 | Go Therapeutics, Inc. | Anti-glyco-muc1 antibodies and their uses |
| WO2022026809A1 (en) * | 2020-07-31 | 2022-02-03 | R.P. Scherer Technologies, Llc | Antibody specific for mucin-1 and methods of use thereof |
| IL311090A (en) * | 2021-08-27 | 2024-04-01 | Peptron Inc | A novel ANTI-MUC1 antibody and its use |
| US20230250190A1 (en) * | 2021-12-21 | 2023-08-10 | Merus N.V. | Binding domains against cancer-associated muc1 |
| CN115068610B (zh) * | 2022-01-27 | 2024-04-16 | 中国农业大学 | 抑制乳腺癌细胞中muc1表达的物质在降低抗乳腺癌药物耐药性中的应用 |
| EP4696711A1 (en) * | 2023-04-13 | 2026-02-18 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen binding molecule specifically binding to egfr and muc1, drug conjugate thereof, and medical use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020146750A1 (en) * | 2000-03-30 | 2002-10-10 | Hoogenboom Hendricus R.J.M. | Mucin-1 specific binding members and methods of use thereof |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US8440798B2 (en) * | 2006-10-04 | 2013-05-14 | Københavns Universitet | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies |
| EP2014302A1 (en) * | 2007-07-12 | 2009-01-14 | Institut Curie | An antibody specific for the Tn antigen for the treatment of cancer |
| AU2008332296A1 (en) * | 2007-12-05 | 2009-06-11 | Kyowa Hakko Kirin Co., Ltd. | Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| JP5773352B2 (ja) * | 2008-10-28 | 2015-09-02 | 塩野義製薬株式会社 | 抗ｍｕｃ１抗体 |
| EP2281844A1 (en) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015120180A1 (en) * | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| US10239950B2 (en) * | 2014-04-28 | 2019-03-26 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof |
| CA3078812A1 (en) * | 2017-10-24 | 2019-05-02 | Go Therapeutics, Inc. | Anti-glyco-muc1 antibodies and their uses |
-
2017
- 2017-10-24 CA CA3078812A patent/CA3078812A1/en active Pending
- 2017-10-24 KR KR1020207014390A patent/KR102608763B1/ko active Active
- 2017-10-24 KR KR1020237040745A patent/KR102832078B1/ko active Active
- 2017-10-24 AU AU2017436815A patent/AU2017436815B2/en active Active
- 2017-10-24 BR BR112020008001-2A patent/BR112020008001A2/pt unknown
- 2017-10-24 CN CN201780097773.8A patent/CN111479828B/zh active Active
- 2017-10-24 EP EP17929557.1A patent/EP3700936A4/en active Pending
- 2017-10-24 JP JP2020543460A patent/JP7358367B2/ja active Active
- 2017-10-24 WO PCT/US2017/058036 patent/WO2019083506A1/en not_active Ceased
- 2017-10-24 MX MX2020004220A patent/MX2020004220A/es unknown
-
2020
- 2020-04-23 IL IL274202A patent/IL274202A/en unknown
-
2023
- 2023-09-27 JP JP2023165289A patent/JP2024001073A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111479828A (zh) | 2020-07-31 |
| EP3700936A4 (en) | 2021-05-26 |
| CN111479828B (zh) | 2024-07-05 |
| BR112020008001A2 (pt) | 2020-10-20 |
| EP3700936A1 (en) | 2020-09-02 |
| KR20230165874A (ko) | 2023-12-05 |
| KR102832078B1 (ko) | 2025-07-08 |
| IL274202A (en) | 2020-06-30 |
| KR20200067885A (ko) | 2020-06-12 |
| KR102608763B1 (ko) | 2023-11-30 |
| JP7358367B2 (ja) | 2023-10-10 |
| WO2019083506A1 (en) | 2019-05-02 |
| JP2024001073A (ja) | 2024-01-09 |
| CA3078812A1 (en) | 2019-05-02 |
| JP2021510307A (ja) | 2021-04-22 |
| AU2017436815B2 (en) | 2025-05-29 |
| AU2017436815A1 (en) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004220A (es) | Anticuerpos anti-glico-muc1 y sus usos. | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| CL2018000458A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| AR107078A1 (es) | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso | |
| MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
| NI201800055A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos. | |
| CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
| CO2018003436A2 (es) | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso | |
| MX395074B (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
| CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
| BR112018070183A2 (pt) | neoantígenos e métodos de seu uso | |
| CL2017001217A1 (es) | Conjugados de droga de anticuerpos. | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| BR112018014615A2 (pt) | composições de anticorpo para ror1 e métodos relacionados | |
| CO2020005347A2 (es) | Anticuerpos y conjugados de anticuerpo-fármaco específicos para cd123 y usos de los mismos | |
| BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
| MX2014015830A (es) | Anticuerpos lsr y usos de los mismos para el tratamiento de cancer. | |
| UY36678A (es) | Anticuerpos anti-fcrn. | |
| UY37630A (es) | Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer | |
| MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. |